★ Top 1% of Universities Worldwide
● Academic Ranking of World Universities
• 2022 Pharmacy and Pharmaceutical Sciences-Top 300 (2nd in Taiwan)
• 2022 World University Ranking-Top 300 (2nd in Taiwan)
● QS World University Rankings by Subject
• 2022 Anatomy & Physiology-Top 100 (2nd in Taiwan)
• 2022 Pharmacy & Pharmacology-Top 150 (2nd in Taiwan)
• 2022 Medicine-Top 250
● THE World University Rankings
• 2022 2022 Clinical, pre-clinical & health-Top 400
• 2022 World University Ranking-Top 300 (2nd in Taiwan)

★ World Renowned Faculty Members
• Mien-Chie Hung, Ph.D. – Cancer Biology and Therapy
• Wen-Hwa Lee, Ph.D. – Molecular Cancer Biology
• Lu-Hai Wang, Ph.D. – Cancer Biology and Oncology
• John S. Kuo, M.D., Ph.D. – Neurosurgery and Neuro-Oncology

★ Centers of Excellence
• Cancer Biology
• Chinese Medicine
• New Drug Development
• Integrative Stem Cell

★ Scholarships for International Graduate Students
• CMU provides scholarships for international graduate students.

Established in 1958, China Medical University (CMU) in Taichung, Taiwan, has since developed into one of the world’s premiere medical research universities with 9 colleges in total: the Colleges of Medicine, Chinese Medicine, Pharmacy, Life Sciences, Public Health, Health Care, Dentistry, Humanities and Technology, and Biomedical Engineering. Its Joint Commission International (JCI)-accredited hospitals have a total of over 6,000 beds, and it is the second largest healthcare system nationwide providing superb service of western and Chinese medicine. CMU is ranked as one of the top 300 universities by Academic Ranking of World Universities 2022, ranked top 350 by Times Higher Education (THE) World University Rankings 2022 and ranked top 50 by 2022 THE Asia University Rankings.

CMU trains both western medicine doctors and Chinese medicine doctors and implements the best integration of western and Chinese medicine at CMU Hospital providing outstanding medical service to patients. As a leader in several research fields with a culture of collaboration and innovation, CMU has made important breakthroughs in cancer treatment such as inventing combined target therapy and immune checkpoint therapy to overcome difficult malignancies, lengthening the survival of glioblastoma patients, discovering ANK-199, a promising anticancer drug that treats head and neck cancer, and identifying the receptor protein IL-17RB that is strongly associated with pancreatic cancer. The Center of Excellence for Chinese Medicine is awarded with Top-Notch Center Grant by Ministry of Education (MOE) Taiwan for 5 years and conducts many lines of clinical studies and discovery of mechanisms underlying the acupuncture-induced anesthesia via opioid-dependent and opioid-independent pathways. The Center of Excellence for New Drug Development is awarded with Top-Notch Center Grant by MOE and aims to develop novel drugs for 5 years.
International collaborative partnerships with prestigious institutions such as Stanford University, the M.D. Anderson Cancer Center, UC Irvine, National University of Singapore, Nanyang Technology University, University of Tokyo, University of Zurich and Seoul National University have been firmly established. Additionally, over 80 international healthcare companies and venture capitalists are assisting the university with its knowledge transfer mission. Thus far, over 60 new drugs have emerged from CMU’s research laboratories, as well as 10 spin-off companies.